PLYMOUTH MEETING, PA., December 16, 2021 / PRNewswire / – The National Comprehensive Cancer Network® (NCCN®The Oncology Research Program (ORP) today announced a collaboration with Pfizer Global Medical Grants (Pfizer) providing new grants to advance understanding of the mechanisms of action, underlying biology and clinical activity of talazoparib in prostate cancer.
“This research will involve innovative investigations on talazoparib and will promote the development of PARP inhibitors in prostate cancer,” said S. Denlinger crystal, MD, FACP, Senior Vice President, Scientific Director, NCCN. “” “Éé
The selected projects are:
- Adam kibel, MD, and Olivier Jonas, PhD, Dana-Farber Brigham Cancer Center
- “Intratumoral microdevice to identify biomarkers and pathways associated with the response to talazoparib”
- Amado Zurita-Saavedra, MD, the University of Texas MD Anderson Cancer Center
- “Phase II presurgical study of talazoparib in combination with enzalutamide in prostate cancer de novo metastatic to lymph nodes”
“We have seen incredible advances in the treatment of prostate cancer over the past decade, however, there is still a need for continuous innovation to support improved patient outcomes,” said Dr. Roxanne ferdinand, Global Medical Manager, Genitourinary (GU) Franchise, Pfizer Oncology. “Pfizer is committed to working with professional organizations such as the NCCN to fund research that helps advance our understanding of how different therapies can meet unmet need. We look forward to seeing how these efforts help advance patient care. ”
The proposals were peer reviewed by a scientific review committee, made up of leading expert oncologists from NCCN member institutions. The priority areas selected will focus on the clinical development of talazoparib combinations, defining biomarkers predictive of clinical benefit. The studies should be completed within two years. Collectively, the total grant amount awarded for this study is approximately $ 1.5 million.
The NCCN ORP encourages innovation and the discovery of knowledge that improves the lives of people with cancer and supports preclinical, translational and clinical research and quality improvement projects in oncology at NCCN member institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resource website, informed consent database, and best practice points of reference for bio-repositories, registries and clinics. data base. For more information, visit NCCN.org/orp.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a non-profit alliance of leading cancer centers dedicated to patient care, research and education. The NCCN is dedicated to improving and facilitating quality, efficient, equitable and accessible cancer care so that all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based expert consensus recommendations for cancer treatment, prevention and support services; they are the recognized standard for clinical direction and policy in cancer management and the most comprehensive and frequently updated clinical practice guidelines available in all areas of medicine. the NCCN guidelines for patients® provide specialist information on cancer treatment to inform and empower patients and caregivers, with support from the NCCN Foundation®. The NCCN is also making progress continuing education, global initiatives, Politics, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg and Twitter @NCCN.
SOURCE Global National Cancer Control Network